Abingworth LLP - 21 Mar 2022 Form 4 Insider Report for Jasper Therapeutics, Inc. (JSPR)

Reporting relationship: 10%+ Owner
Issuer ticker: JSPR
Reported as of: 21 Mar 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Mar 2022, 17:30:38 UTC
Prior SEC filing: 01 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ John Heard

Key filing fact

Abingworth LLP filed Form 4 for Jasper Therapeutics, Inc. (JSPR) on 23 Mar 2022.

Key facts

This page summarizes Abingworth LLP's Form 4 filing for Jasper Therapeutics, Inc. (JSPR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Mar 2022, 17:30.

Change

Previous filing in this sequence was filed on 01 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JSPR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +78,045
Change %
Price: $0.000000
Shares after: 78,045
Date: 21 Mar 2022
Ownership: See footnotes
Underlying class: Voting Common Stock
Underlying amount: 78,045
Exercise price: $3.54
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Abingworth Bioventures VII GP LP ("Abingworth GP") serves as the general partner of Abingworth Bioventures VII, LP ("ABV VII"). Abingworth General Partner VII LLP serves as the general partner of Abingworth GP. ABV VII (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VII LLP) has delegated to the Reporting Person all investment and dispositive power over the securities held by ABV VII.

Footnote F2

The option (the "Option") was granted to Kurt von Emster, a director of the Issuer and a member of the investment committee of ABV VII (the "Investment Committee") which approves investment and voting decisions by majority vote. No individual member of the Investment Committee has the sole control or voting power over the securities held by ABV VII. The Option will vest in equal annual installments over three years, commencing on December 7, 2022, subject to the Mr. von Emster's continued service with the Issuer through each vesting date. Under an agreement between Mr. von Emster and the Reporting Person, Mr. von Emster is deemed to hold the Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of the Reporting Person.

Footnote F3

ABV VII may be deemed the indirect beneficial owner of the Option, and Mr. von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. Each of ABV VII, Abingworth GP, Abingworth General Partner VII LLP, Mr. von Emster, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.